CAI · Caris Life Sciences Inc
United States · RS rating 93 · As of 2026-10-14
| Price | 30.25 USD |
|---|---|
| 1-day change | +2.5% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 90 / 97 / 45 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 60 / 49 / 75 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +250.0% |
| Sales growth Q/Q | +35.1% |
| Distance from 52-week high | +6.2% |
| Market cap (USD) | $5.6B |